These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 2957716)

  • 1. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride.
    Farde L; Halldin C; Stone-Elander S; Sedvall G
    Psychopharmacology (Berl); 1987; 92(3):278-84. PubMed ID: 2957716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans--a PET study with [11C]SCH 23390 and [11C]raclopride.
    Farde L
    Psychopharmacology (Berl); 1992; 107(1):23-9. PubMed ID: 1534178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central D1- and D2-receptor occupancy during antipsychotic drug treatment.
    Wiesel FA; Farde L; Nordström AL; Sedvall G
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):759-67. PubMed ID: 1981395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective binding of 11C-raclopride in living human brain--a search for extrastriatal central D2-dopamine receptors by PET.
    Farde L; Pauli S; Hall H; Eriksson L; Halldin C; Högberg T; Nilsson L; Sjögren I; Stone-Elander S
    Psychopharmacology (Berl); 1988; 94(4):471-8. PubMed ID: 3131792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain.
    Andersen PH
    Eur J Pharmacol; 1988 Jan; 146(1):113-20. PubMed ID: 2895008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human dopamine receptor subtypes--in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride.
    Hall H; Farde L; Sedvall G
    J Neural Transm; 1988; 73(1):7-21. PubMed ID: 2969950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.
    Farde L; Nordström AL; Wiesel FA; Pauli S; Halldin C; Sedvall G
    Arch Gen Psychiatry; 1992 Jul; 49(7):538-44. PubMed ID: 1352677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain.
    Hall H; Sedvall G; Magnusson O; Kopp J; Halldin C; Farde L
    Neuropsychopharmacology; 1994 Dec; 11(4):245-56. PubMed ID: 7531978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.
    Farde L; Wiesel FA; Stone-Elander S; Halldin C; Nordström AL; Hall H; Sedvall G
    Arch Gen Psychiatry; 1990 Mar; 47(3):213-9. PubMed ID: 1968328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The benzazepine, SCH 23390, inhibits 3H-NPA binding in mouse brain in vivo.
    Andersen PH; Nielsen EB
    Acta Pharmacol Toxicol (Copenh); 1986 Oct; 59(4):315-8. PubMed ID: 2948372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain.
    Seeman P; Niznik HB; Guan HC; Booth G; Ulpian C
    Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10156-60. PubMed ID: 2574862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current status of PET scanning with respect to schizophrenia.
    Sedvall G
    Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.
    Ginovart N; Lundin A; Farde L; Halldin C; Bäckman L; Swahn CG; Pauli S; Sedvall G
    Brain; 1997 Mar; 120 ( Pt 3)():503-14. PubMed ID: 9126061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET--a comparison to the equilibrium analysis.
    Farde L; Eriksson L; Blomquist G; Halldin C
    J Cereb Blood Flow Metab; 1989 Oct; 9(5):696-708. PubMed ID: 2528555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.
    Farde L; Wiesel FA; Halldin C; Sedvall G
    Arch Gen Psychiatry; 1988 Jan; 45(1):71-6. PubMed ID: 2892477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of radioligands in schizophrenia research.
    Sedvall G; Farde L; Hall H; Halldin C; Karlsson P; Nordström AL; Nyberg S; Pauli S
    Clin Neurosci; 1995; 3(2):112-21. PubMed ID: 7583617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.
    Farde L; Hall H; Ehrin E; Sedvall G
    Science; 1986 Jan; 231(4735):258-61. PubMed ID: 2867601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients.
    Farde L; Suhara T; Nyberg S; Karlsson P; Nakashima Y; Hietala J; Halldin C
    Psychopharmacology (Berl); 1997 Oct; 133(4):396-404. PubMed ID: 9372541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 11C-SCH 39166, a selective ligand for visualization of dopamine-D1 receptor binding in the monkey brain using PET.
    Sedvall G; Farde L; Barnett A; Hall H; Halldin C
    Psychopharmacology (Berl); 1991; 103(2):150-3. PubMed ID: 1674157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential modulation of dopamine D1-receptor binding and mRNA expression in the basal ganglia by the D1-receptor antagonist, SCH-23390.
    Yu J; Coirini H; Källström L; Wiesel FA; Johnson AE
    Synapse; 1998 Sep; 30(1):38-48. PubMed ID: 9704879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.